Evidence suggests that HSPA4 is implicated in the pathogenesis and progression of hepatocellular carcinoma [15], colorectal cancer [16], gastric cancer [17], and head and neck cancer [14], positioning it as a potential therapeutic target and prognostic biomarker. Here, HSPA4 is linked to colorectal cancer.